Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Plus ADI-PEG 20 in Resectable HCC
NCT04965714Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2022
- Primary completion
- Feb 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, Pegargiminase in hepatocellular carcinoma (HCC), sponsored by University of Texas MD Anderson Cancer Center. Planned start Apr 2022; status: withdrawn.
02
Drugs
nivolumabPegargiminase
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04965714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04965714.